By integrating both direct and indirect evidence, our network meta-analysis shows that plerixafor plus G-CSF SD is inferior to ID-AraC plus G-CSF SD, but superior to CY plus G-CSF RD in consideration of the rank probabilities regarding to the number of collected CD34+ cells and the rate of successful mobilization in patients with MM. This evidence concerns the gene CD34 and Miyoshi myopathy.